News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lundbeck Inc. (LUN.CO) and Otsuka Pharmaceutical Co., Ltd. Take Alcohol Drug to Japan in $136 Million+ Pact



10/31/2013 7:27:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Lundbeck has expanded its alliance with Otsuka Pharmaceutical Co to include development and commercialisation of the alcohol dependence drug Selincro in Japan. Selincro (nalmefene) was approved by the European Medicines Agency earlier this year and the two partners say the first Phase III study for Japan will be initiated during 2014. Under the terms of the agreement, Lundbeck will pocket a 50 million euro fee, finance the development costs and have an option to co-promote in Japan.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES